MAPT and Alzheimer disease: For years, hallmarks of AD (tau protein, neurofibrillary tangles, amyloid plaques) which are known to correlate with declining cognitive abilities have captured the research spotlight, but linked treatments have shown poor translation to the bedside [48–52], with critical questions raised about efficacy and side-effect profiles.